ArcticZymes develops and markets recombinant enzymes for use in life science research and in the molecular diagnostics sector. The enzymes are derived from cold-water marine species and offer novel functionality to customer products.
The business idea of the late 1980’s was to exploit by-products from the fishing industry of Northern Norway. In the mid-1990’s, Biotec Pharmacon acquired the technology for production of Shrimp Alkaline Phosphatase and built a department for the production of molecular grade enzymes. Later a number of additional enzyme products were developed and launched.
In 2009, Biotec Pharmacon organized these activities in its subsidiary ArcticZymes AS. The leadership at ArcticZymes recognizes the critical role enzymes play in research and diagnostics. The company has therefore developed strong relationships with OEM partners and individual researchers alike, with the strategic intent to expand their enzyme portfolio and the application of each unique product. ArcticZymes’ products are sold worldwide.
The company aims to continue to develop new enzymes for molecular biotechnology in the future, which will be facilitated by its 15 partner organisations within industry and research, and furthermore funds received from the European Framework Programme for Research and Innovation, Horizon 2020.